Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 10:05
11/08/22
11/08
10:05
11/08/22
10:05
RCKT

Rocket Pharmaceuticals

$16.75 /

+0.54 (+3.33%)

, KYMR

Kymera Therapeutics

$29.37 /

+0.24 (+0.82%)

, BKSY

BlackSky

$1.73 /

-0.065 (-3.62%)

, PL

Planet Labs

$5.44 /

+0.045 (+0.83%)

, TSHA

Taysha Gene Therapies

$2.11 /

+0.125 (+6.30%)

, VRSK

Verisk Analytics

$169.78 /

+1.31 (+0.78%)

, JACK

Jack in the Box

$84.75 /

-1.55 (-1.80%)

, JELD

Jeld-Wen

$9.30 /

-0.15 (-1.59%)

, SIX

Six Flags

$19.98 /

-1.17 (-5.53%)

, WSM

Williams-Sonoma

$119.10 /

-4.25 (-3.45%)

, LYFT

Lyft

$11.37 /

-2.775 (-19.62%)

, MTD

Mettler-Toledo

$1,305.00 /

+7.21 (+0.56%)

, SMG

Scotts Miracle-Gro

$53.97 /

+2.315 (+4.48%)

, PLAY

Dave & Buster's

$37.66 /

+0.62 (+1.67%)

, SQ

Block

$60.64 /

-1.95 (-3.12%)

Institutional investors…

ShowHide Related Items >><<
WSM Williams-Sonoma
$119.10 /

-4.25 (-3.45%)

VRSK Verisk Analytics
$169.78 /

+1.31 (+0.78%)

TSHA Taysha Gene Therapies
$2.11 /

+0.125 (+6.30%)

SQ Block
$60.64 /

-1.95 (-3.12%)

SMG Scotts Miracle-Gro
$53.97 /

+2.315 (+4.48%)

SIX Six Flags
$19.98 /

-1.17 (-5.53%)

RCKT Rocket Pharmaceuticals
$16.75 /

+0.54 (+3.33%)

PLAY Dave & Buster's
$37.66 /

+0.62 (+1.67%)

PL Planet Labs
$5.44 /

+0.045 (+0.83%)

MTD Mettler-Toledo
$1,305.00 /

+7.21 (+0.56%)

LYFT Lyft
$11.37 /

-2.775 (-19.62%)

KYMR Kymera Therapeutics
$29.37 /

+0.24 (+0.82%)

JELD Jeld-Wen
$9.30 /

-0.15 (-1.59%)

JACK Jack in the Box
$84.75 /

-1.55 (-1.80%)

BKSY BlackSky
$1.73 /

-0.065 (-3.62%)

RCKT Rocket Pharmaceuticals
$16.75 /

+0.54 (+3.33%)

11/07/22 Canaccord
Rocket Pharmaceuticals initiated with a Buy at Canaccord
11/01/22 BTIG
Rocket Pharmaceuticals initiated with a Buy at BTIG
09/30/22 Chardan
Rocket Pharmaceuticals price target raised to $65 from $62 at Chardan
09/30/22 Evercore ISI
Rocket Pharmaceuticals price target raised to $75 from $65 at Evercore ISI
KYMR Kymera Therapeutics
$29.37 /

+0.24 (+0.82%)

11/08/22 Raymond James
Kymera Therapeutics initiated with a Market Perform at Raymond James
11/07/22 B. Riley
Kymera Therapeutics price target lowered to $35 from $50 at B. Riley
08/31/22 JPMorgan
Kymera selloff a 'misplaced knee-jerk reaction,' says JPMorgan
08/15/22 Jefferies
Kymera Therapeutics initiated with a Buy at Jefferies
BKSY BlackSky
$1.73 /

-0.065 (-3.62%)

11/08/22 Deutsche Bank
BlackSky initiated with a Buy at Deutsche Bank
10/11/22 Credit Suisse
BlackSky initiated with Outperform on growth momentum at Credit Suisse
10/11/22 Credit Suisse
BlackSky initiated with an Outperform at Credit Suisse
07/26/22 Lake Street
BlackSky initiated with a Buy at Lake Street
PL Planet Labs
$5.44 /

+0.045 (+0.83%)

11/08/22 Deutsche Bank
Planet Labs initiated with a Buy at Deutsche Bank
09/13/22 Needham
Planet Labs price target raised to $9 from $8 at Needham
06/15/22 Craig-Hallum
Planet Labs price target lowered to $10 from $15 at Craig-Hallum
06/15/22 Needham
Planet Labs price target lowered to $8.00 from $10.50 at Needham
TSHA Taysha Gene Therapies
$2.11 /

+0.125 (+6.30%)

11/08/22 Guggenheim
Taysha Gene Therapies price target lowered to $19 from $22 at Guggenheim
11/08/22 Needham
Taysha Gene Therapies price target lowered to $16 from $18 at Needham
11/08/22 Canaccord
Taysha Gene Therapies initiated with a Buy at Canaccord
10/26/22 Truist
Taysha Gene Therapies price target lowered to $15 from $35 at Truist
VRSK Verisk Analytics
$169.78 /

+1.31 (+0.78%)

11/08/22 Morgan Stanley
Verisk Analytics resumed with an Equal Weight at Morgan Stanley
11/03/22 Baird
Verisk Analytics price target lowered to $201 from $220 at Baird
10/25/22 Jefferies
Verisk Analytics assumed with a Buy at Jefferies
10/24/22 Deutsche Bank
Verisk Analytics price target lowered to $195 from $227 at Deutsche Bank
JACK Jack in the Box
$84.75 /

-1.55 (-1.80%)

11/08/22 Deutsche Bank
Jack in the Box downgraded to Hold from Buy at Deutsche Bank
09/21/22 Wolfe Research
Jack in the Box initiated with a Peer Perform at Wolfe Research
09/12/22 Wedbush
Wedbush ups Jack in the Box price target to $115, adds to Best Ideas List
08/30/22 Wedbush
Jack in the Box 'most exposed' to direct impact from AB 257, says Wedbush
JELD Jeld-Wen
$9.30 /

-0.15 (-1.59%)

11/08/22 Wolfe Research
Jeld-Wen downgraded to Underperform at Wolfe Research on developing pressures
11/08/22 Wolfe Research
Jeld-Wen downgraded to Underperform from Peer Perform at Wolfe Research
11/01/22 B. Riley
Jeld-Wen price target lowered to $10 from $17 at B. Riley
11/01/22 Barclays
Jeld-Wen price target lowered to $10 from $15 at Barclays
SIX Six Flags
$19.98 /

-1.17 (-5.53%)

11/08/22 Jefferies
Six Flags downgraded to Hold at Jefferies ahead of 'transition' Q3
11/08/22 Jefferies
Six Flags downgraded to Hold from Buy at Jefferies
11/02/22 Deutsche Bank
Six Flags price target lowered to $32 from $38 at Deutsche Bank
10/31/22 B. Riley
Six Flags price target lowered to $23 from $24 at B. Riley
WSM Williams-Sonoma
$119.10 /

-4.25 (-3.45%)

11/08/22 Wedbush
Wedbush downgrades Williams-Sonoma to Neutral, lowers price target to $110
11/08/22 Wedbush
Williams-Sonoma downgraded to Neutral from Outperform at Wedbush
10/31/22 Citi
Williams-Sonoma price target lowered to $135 from $156 at Citi
10/24/22 Jefferies
Williams-Sonoma downgraded to Underperform from Hold at Jefferies
LYFT Lyft
$11.37 /

-2.775 (-19.62%)

11/08/22 DA Davidson
Lyft price target lowered to $19 from $25 at DA Davidson
11/08/22 BofA
Lyft price target lowered to $11.50 from $14 at BofA
11/08/22 Wedbush
Lyft price target lowered to $17 from $25 at Wedbush
11/08/22 Cowen
Lyft price target lowered to $36 from $42 at Cowen
MTD Mettler-Toledo
$1,305.00 /

+7.21 (+0.56%)

11/08/22 Goldman Sachs
Mettler-Toledo upgraded to Neutral from Sell at Goldman Sachs
11/04/22 Baird
Mettler-Toledo price target lowered to $1284 from $1406 at Baird
09/06/22 Stifel
Mettler-Toledo upgraded to Buy at Stifel after 30% year-to-date pullback
09/06/22 Stifel
Mettler-Toledo upgraded to Buy from Hold at Stifel
SMG Scotts Miracle-Gro
$53.97 /

+2.315 (+4.48%)

11/08/22 Barclays
Scotts Miracle-Gro upgraded to Overweight from Equal Weight at Barclays
11/03/22 Truist
Scotts Miracle-Gro price target lowered to $50 from $85 at Truist
11/03/22 Raymond James
Scotts Miracle-Gro price target lowered to $56 from $100 at Raymond James
10/27/22 Stifel
Scotts Miracle-Gro price target lowered to $48 from $75 at Stifel
PLAY Dave & Buster's
$37.66 /

+0.62 (+1.67%)

11/08/22 Deutsche Bank
Dave & Buster's upgraded to Buy from Hold at Deutsche Bank
10/05/22 Piper Sandler
Dave & Buster's price target lowered to $34 from $44 at Piper Sandler
09/09/22 Deutsche Bank
Dave & Buster's price target raised to $48 from $37 at Deutsche Bank
09/08/22 Truist
Dave & Buster's price target raised to $62 from $57 at Truist
SQ Block
$60.64 /

-1.95 (-3.12%)

11/07/22 Macquarie
Block upgraded to Outperform from Neutral at Macquarie
11/06/22 Barclays
Block price target lowered to $100 from $130 at Barclays
11/04/22 BTIG
Block price target lowered to $100 from $175 at BTIG
11/02/22 Evercore ISI
Block added to 'Tactical Underperform' list at Evercore ISI
WSM Williams-Sonoma
$119.10 /

-4.25 (-3.45%)

VRSK Verisk Analytics
$169.78 /

+1.31 (+0.78%)

TSHA Taysha Gene Therapies
$2.11 /

+0.125 (+6.30%)

SQ Block
$60.64 /

-1.95 (-3.12%)

SMG Scotts Miracle-Gro
$53.97 /

+2.315 (+4.48%)

SIX Six Flags
$19.98 /

-1.17 (-5.53%)

RCKT Rocket Pharmaceuticals
$16.75 /

+0.54 (+3.33%)

PLAY Dave & Buster's
$37.66 /

+0.62 (+1.67%)

PL Planet Labs
$5.44 /

+0.045 (+0.83%)

MTD Mettler-Toledo
$1,305.00 /

+7.21 (+0.56%)

LYFT Lyft
$11.37 /

-2.775 (-19.62%)

KYMR Kymera Therapeutics
$29.37 /

+0.24 (+0.82%)

JELD Jeld-Wen
$9.30 /

-0.15 (-1.59%)

JACK Jack in the Box
$84.75 /

-1.55 (-1.80%)

BKSY BlackSky
$1.73 /

-0.065 (-3.62%)

  • 27
    Oct
  • 04
    Oct
  • 08
    Sep
SQ Block
$60.64 /

-1.95 (-3.12%)

SMG Scotts Miracle-Gro
$53.97 /

+2.315 (+4.48%)

SIX Six Flags
$19.98 /

-1.17 (-5.53%)

LYFT Lyft
$11.37 /

-2.775 (-19.62%)

JACK Jack in the Box
$84.75 /

-1.55 (-1.80%)

WSM Williams-Sonoma
$119.10 /

-4.25 (-3.45%)

TSHA Taysha Gene Therapies
$2.11 /

+0.125 (+6.30%)

SQ Block
$60.64 /

-1.95 (-3.12%)

SMG Scotts Miracle-Gro
$53.97 /

+2.315 (+4.48%)

SIX Six Flags
$19.98 /

-1.17 (-5.53%)

RCKT Rocket Pharmaceuticals
$16.75 /

+0.54 (+3.33%)

PLAY Dave & Buster's
$37.66 /

+0.62 (+1.67%)

PL Planet Labs
$5.44 /

+0.045 (+0.83%)

MTD Mettler-Toledo
$1,305.00 /

+7.21 (+0.56%)

LYFT Lyft
$11.37 /

-2.775 (-19.62%)

KYMR Kymera Therapeutics
$29.37 /

+0.24 (+0.82%)

JELD Jeld-Wen
$9.30 /

-0.15 (-1.59%)

JACK Jack in the Box
$84.75 /

-1.55 (-1.80%)

BKSY BlackSky
$1.73 /

-0.065 (-3.62%)

WSM Williams-Sonoma
$119.10 /

-4.25 (-3.45%)

SQ Block
$60.64 /

-1.95 (-3.12%)

SIX Six Flags
$19.98 /

-1.17 (-5.53%)

PLAY Dave & Buster's
$37.66 /

+0.62 (+1.67%)

PL Planet Labs
$5.44 /

+0.045 (+0.83%)

MTD Mettler-Toledo
$1,305.00 /

+7.21 (+0.56%)

LYFT Lyft
$11.37 /

-2.775 (-19.62%)

Initiation
Rocket Pharmaceuticals initiated with a Buy at Canaccord » 16:17
11/07/22
11/07
16:17
11/07/22
16:17
RCKT

Rocket Pharmaceuticals

$16.25 /

-0.755 (-4.44%)

Canaccord analyst Whitney…

Canaccord analyst Whitney Ijem initiated coverage of Rocket Pharmaceuticals with a Buy rating and $53 price target. The shares "provide an opportunity to gain exposure to the gene therapy space in a diversified way," both on the technology and stage-of-development fronts, Ijem tells investors. Rocket's late-stage pipeline includes two programs with line of sight to commercialization with regulatory filings in the U.S. and EU expected next year with "more to come," the analyst said.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$16.25 /

-0.755 (-4.44%)

RCKT Rocket Pharmaceuticals
$16.25 /

-0.755 (-4.44%)

11/01/22 BTIG
Rocket Pharmaceuticals initiated with a Buy at BTIG
09/30/22 Chardan
Rocket Pharmaceuticals price target raised to $65 from $62 at Chardan
09/30/22 Evercore ISI
Rocket Pharmaceuticals price target raised to $75 from $65 at Evercore ISI
09/27/22 UBS
Rocket Pharmaceuticals price target cut to $62, named new top SMID pick at UBS
RCKT Rocket Pharmaceuticals
$16.25 /

-0.755 (-4.44%)

  • 04
    Oct
RCKT Rocket Pharmaceuticals
$16.25 /

-0.755 (-4.44%)

Over a month ago
Earnings
Rocket Pharmaceuticals reports Q3 EPS (87c), consensus (79c) » 16:13
11/03/22
11/03
16:13
11/03/22
16:13
RCKT

Rocket Pharmaceuticals

$17.82 /

-0.32 (-1.76%)

"Rocket had a…

"Rocket had a remarkable third quarter highlighted by significant progress in our Phase 1 clinical trial for Danon Disease, with positive early findings demonstrating RP-A501 was generally well tolerated with evidence of positive treatment effect and improvement of the natural course of the disease in pediatric patients with up to nine months follow-up. Additionally, we observed continued, durable robust activity in adults with up to 36 months follow-up," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. "As previously announced, we reached an understanding with the FDA on chemistry, manufacturing and controls (CMC) requirements to start AAV cGMP manufacturing at our in-house facility as well as potency assay plans for a Phase 2 pivotal study. We are now laser focused on advancing Phase 2 pivotal study design and endpoint selection with FDA feedback expected this quarter Finally, our exceptional third quarter progress was capped off by an extension of our cash runway into the second half of 2024 following an equity raise with net proceeds of $108.2 million. Taken together, I am very proud of our continued progress at Rocket and look forward to the final push towards another successful year in our pursuit of gene therapy cures for patients and their loved ones facing these devastating, life-threatening genetic diseases."

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$17.82 /

-0.32 (-1.76%)

RCKT Rocket Pharmaceuticals
$17.82 /

-0.32 (-1.76%)

11/01/22 BTIG
Rocket Pharmaceuticals initiated with a Buy at BTIG
09/30/22 Chardan
Rocket Pharmaceuticals price target raised to $65 from $62 at Chardan
09/30/22 Evercore ISI
Rocket Pharmaceuticals price target raised to $75 from $65 at Evercore ISI
09/27/22 UBS
Rocket Pharmaceuticals price target cut to $62, named new top SMID pick at UBS
RCKT Rocket Pharmaceuticals
$17.82 /

-0.32 (-1.76%)

  • 04
    Oct
RCKT Rocket Pharmaceuticals
$17.82 /

-0.32 (-1.76%)

Initiation
Rocket Pharmaceuticals initiated with a Buy at BTIG » 06:29
11/01/22
11/01
06:29
11/01/22
06:29
RCKT

Rocket Pharmaceuticals

$18.63 /

-0.3 (-1.58%)

BTIG analyst Yun Zhong…

BTIG analyst Yun Zhong initiated coverage of Rocket Pharmaceuticals with a Buy rating and $35 price target. The company has assembled a robust gene therapy pipeline and with the recently announced acquisition of Renovacor as it continues to expand the combined market potential that the company's portfolio can target, the analyst tells investors in a research note. Virtually all prior efforts in developing cardiac gene therapies have failed, but Rocket's clinical data to date from both adult and pediatric patients have demonstrated robust protein expression and durable histological changes that are consistent across different age groups, Zhong adds.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$18.63 /

-0.3 (-1.58%)

RCKT Rocket Pharmaceuticals
$18.63 /

-0.3 (-1.58%)

09/30/22 Chardan
Rocket Pharmaceuticals price target raised to $65 from $62 at Chardan
09/30/22 Evercore ISI
Rocket Pharmaceuticals price target raised to $75 from $65 at Evercore ISI
09/27/22 UBS
Rocket Pharmaceuticals price target cut to $62, named new top SMID pick at UBS
09/21/22 Baird
Renovacor downgraded to Neutral from Outperform at Baird
RCKT Rocket Pharmaceuticals
$18.63 /

-0.3 (-1.58%)

  • 04
    Oct
RCKT Rocket Pharmaceuticals
$18.63 /

-0.3 (-1.58%)

On The Fly
Fly Insider: Enviva, AMD among week's notable insider trades » 15:01
10/17/22
10/17
15:01
10/17/22
15:01
EVA

Enviva

$53.13 /

+5.22 (+10.90%)

, RCKT

Rocket Pharmaceuticals

$17.32 /

+0.985 (+6.03%)

, CCO

Clear Channel Outdoor

$1.58 /

+0.13 (+8.97%)

, COIN

Coinbase

$69.75 /

+6.2 (+9.76%)

, AAON

Aaon

$55.57 /

+1.32 (+2.43%)

, AHCO

AdaptHealth

$21.21 /

+0.525 (+2.54%)

, AMD

AMD

$58.08 /

+2.11 (+3.77%)

, AN

AutoNation

$101.74 /

+0.53 (+0.52%)

Welcome to "Fly Insider,"…

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$17.32 /

+0.985 (+6.03%)

EVA Enviva
$53.13 /

+5.22 (+10.90%)

COIN Coinbase
$69.75 /

+6.2 (+9.76%)

CCO Clear Channel Outdoor
$1.58 /

+0.13 (+8.97%)

AN AutoNation
$101.74 /

+0.53 (+0.52%)

AMD AMD
$58.08 /

+2.11 (+3.77%)

AHCO AdaptHealth
$21.21 /

+0.525 (+2.54%)

AAON Aaon
$55.57 /

+1.32 (+2.43%)

EVA Enviva
$53.13 /

+5.22 (+10.90%)

10/18/22 Raymond James
Enviva upgraded to Strong Buy from Outperform at Raymond James
10/14/22 Citi
Citi upgrades Enviva to Buy, says short report selloff overdone
10/14/22 Citi
Enviva upgraded to Buy from Neutral at Citi
10/12/22 Raymond James
Enviva short report claims 'old news' or 'erroneous,' says Raymond James
RCKT Rocket Pharmaceuticals
$17.32 /

+0.985 (+6.03%)

09/30/22 Chardan
Rocket Pharmaceuticals price target raised to $65 from $62 at Chardan
09/30/22 Evercore ISI
Rocket Pharmaceuticals price target raised to $75 from $65 at Evercore ISI
09/27/22 UBS
Rocket Pharmaceuticals price target cut to $62, named new top SMID pick at UBS
09/21/22 Baird
Renovacor downgraded to Neutral from Outperform at Baird
CCO Clear Channel Outdoor
$1.58 /

+0.13 (+8.97%)

07/08/22 Wells Fargo
Clear Channel Outdoor cut to Equal Weight at Wells in anticipation of recession
07/08/22 Wells Fargo
Clear Channel Outdoor downgraded to Equal Weight from Overweight at Wells Fargo
07/07/22 Citi
Clear Channel Outdoor price target lowered to $1.25 from $1.65 at Citi
06/10/22 Morgan Stanley
Clear Channel price target lowered to $2.15 from $2.50 at Morgan Stanley
COIN Coinbase
$69.75 /

+6.2 (+9.76%)

10/11/22 JMP Securities
Coinbase price target lowered to $155 from $195 at JMP Securities
10/10/22 Barclays
Coinbase price target raised to $77 from $73 at Barclays
09/30/22 DA Davidson
DA Davidson cuts Coinbase EBITDA estimates while turning 'increasingly bullish'
09/29/22 Wells Fargo
Coinbase initiated with an Underweight at Wells Fargo
AAON Aaon
$55.57 /

+1.32 (+2.43%)

09/15/22 CJS Securities
Aaon initiated with an Outperform at CJS Securities
08/09/22 DA Davidson
Aaon price target raised to $72 from $70 at DA Davidson
05/06/22 DA Davidson
Aaon upgraded to Buy from Neutral at DA Davidson
05/06/22 DA Davidson
Aaon upgraded to Buy from Neutral at DA Davidson
AHCO AdaptHealth
$21.21 /

+0.525 (+2.54%)

10/11/22 BofA
AdaptHealth, HealthEquity, ViaSat added to 'Endeavor List' at BofA
09/20/22 Deutsche Bank
AdaptHealth price target raised to $28 from $26 at Deutsche Bank
09/19/22 Truist
AdaptHealth price target raised to $28 from $26 at Truist
09/19/22 Baird
AdaptHealth designated as a bullish Fresh Pick at Baird
AMD AMD
$58.08 /

+2.11 (+3.77%)

10/18/22 Deutsche Bank
AMD price target lowered to $70 from $80 at Deutsche Bank
10/10/22 Northland
AMD price target lowered to $80 from $105 at Northland
10/10/22 Cowen
AMD price target lowered to $100 from $120 at Cowen
10/10/22 Citi
AMD price target lowered to $65 from $96 at Citi
AN AutoNation
$101.74 /

+0.53 (+0.52%)

10/06/22 JPMorgan
AutoNation downgraded to Neutral from Overweight at JPMorgan
09/09/22 BofA
AutoNation price target lowered to $238 from $250 at BofA
08/23/22 Argus
Argus starts AutoNation at Buy, sees technology boosting sales and margins
08/23/22 Argus
AutoNation initiated with a Buy at Argus
RCKT Rocket Pharmaceuticals
$17.32 /

+0.985 (+6.03%)

EVA Enviva
$53.13 /

+5.22 (+10.90%)

COIN Coinbase
$69.75 /

+6.2 (+9.76%)

CCO Clear Channel Outdoor
$1.58 /

+0.13 (+8.97%)

AN AutoNation
$101.74 /

+0.53 (+0.52%)

AMD AMD
$58.08 /

+2.11 (+3.77%)

AHCO AdaptHealth
$21.21 /

+0.525 (+2.54%)

AAON Aaon
$55.57 /

+1.32 (+2.43%)

  • 04
    Oct
  • 20
    Jan
EVA Enviva
$53.13 /

+5.22 (+10.90%)

COIN Coinbase
$69.75 /

+6.2 (+9.76%)

AMD AMD
$58.08 /

+2.11 (+3.77%)

RCKT Rocket Pharmaceuticals
$17.32 /

+0.985 (+6.03%)

EVA Enviva
$53.13 /

+5.22 (+10.90%)

COIN Coinbase
$69.75 /

+6.2 (+9.76%)

CCO Clear Channel Outdoor
$1.58 /

+0.13 (+8.97%)

AN AutoNation
$101.74 /

+0.53 (+0.52%)

AMD AMD
$58.08 /

+2.11 (+3.77%)

AHCO AdaptHealth
$21.21 /

+0.525 (+2.54%)

AAON Aaon
$55.57 /

+1.32 (+2.43%)

COIN Coinbase
$69.75 /

+6.2 (+9.76%)

AMD AMD
$58.08 /

+2.11 (+3.77%)

Hot Stocks
Rocket Pharmaceuticals to present lentiviral gene therapies at ESGCT Congress » 06:18
10/12/22
10/12
06:18
10/12/22
06:18
RCKT

Rocket Pharmaceuticals

$16.50 /

-0.2 (-1.20%)

Rocket Pharmaceuticals…

Rocket Pharmaceuticals announced data presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy - ESGCT - in Edinburgh October 11-14. Presentations will include clinical data from Rocket's lentiviral vector-based gene therapy programs for Leukocyte Adhesion Deficiency-I or LAD-I, Fanconi Anemia or FA, and Pyruvate Kinase Deficiency or PKD. The poster and presentation include updated safety and efficacy data from the Phase 2 pivotal trial of RP-L102, Rocket's lentiviral gene therapy candidate for FA. At six months post-infusion, at least one additional patient has demonstrated early signs of engraftment, at levels similar to the five of nine evaluable patients who had increased bone marrow cell resistance to mitomycin-C, ranging from 51% to 94% at 18-24 months, and sustained greater than or equal to20% at consecutive timepoints post RP-L102 infusion. The patient tolerated induction chemotherapy and is currently in complete remission. The presence of RP-L102 mediated gene corrected hematopoietic cells may have facilitated the patient's tolerance of anti-cancer therapy. Regulatory filings continue to be anticipated in 2023. RP-L201 is Rocket's ex-vivo lentiviral gene therapy candidate for the treatment of severe LAD-I. Observed 100% overall survival at 12 months post-infusion and a statistically significant reduction in all hospitalizations, infection- and inflammatory-related hospitalizations and prolonged hospitalizations for all nine LAD-I patients with three to 24 months of available follow-up. The safety profile of RP-L201 has been highly favorable in all patients with no RP-L201-related serious adverse events to date. Rocket has initiated discussions with the FDA and anticipates regulatory filings in the first half of 2023. A poster and presentation include previously disclosed safety and efficacy data from the Phase 1 trial of RP-L301, Rocket's ex-vivo lentiviral gene therapy candidate for the treatment of PKD. At 18 months post-infusion, both adult patients have sustained transgene expression, normalized hemoglobin, improved hemolysis, no red blood cell transfusion requirements post-engraftment and improved quality of life both reported anecdotally and as documented via formal quality of life assessments. The safety profile of RP-L301 appears favorable, with no IP-related serious adverse events 18 months post-infusion. Pediatric patients are currently being enrolled and treated.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$16.50 /

-0.2 (-1.20%)

RCKT Rocket Pharmaceuticals
$16.50 /

-0.2 (-1.20%)

09/30/22 Chardan
Rocket Pharmaceuticals price target raised to $65 from $62 at Chardan
09/30/22 Evercore ISI
Rocket Pharmaceuticals price target raised to $75 from $65 at Evercore ISI
09/27/22 UBS
Rocket Pharmaceuticals price target cut to $62, named new top SMID pick at UBS
09/21/22 Baird
Renovacor downgraded to Neutral from Outperform at Baird
RCKT Rocket Pharmaceuticals
$16.50 /

-0.2 (-1.20%)

  • 04
    Oct
RCKT Rocket Pharmaceuticals
$16.50 /

-0.2 (-1.20%)

On The Fly
Fly Intel: Pre-market Movers » 08:48
10/04/22
10/04
08:48
10/04/22
08:48
TSLA

Tesla

$242.24 /

-23.1 (-8.71%)

, POSH

Poshmark

$15.57 /

-0.11 (-0.70%)

, ADEA

Adeia

$7.19 /

+0.54 (+8.12%)

, EXEL

Exelixis

$16.36 /

+0.68 (+4.34%)

, BBBY

Bed Bath & Beyond

$5.99 /

-0.12 (-1.96%)

, RIVN

Rivian Automotive

$31.89 /

-1.025 (-3.11%)

, AYI

Acuity Brands

$159.51 /

+1.51 (+0.96%)

, KALV

KalVista

$14.24 /

-0.285 (-1.96%)

, RCKT

Rocket Pharmaceuticals

$15.49 /

-0.49 (-3.07%)

, AXTI

AXT Inc.

$7.00 /

+0.29 (+4.32%)

Check out this morning's…

ShowHide Related Items >><<
TSLA Tesla
$242.24 /

-23.1 (-8.71%)

RIVN Rivian Automotive
$31.89 /

-1.025 (-3.11%)

RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

POSH Poshmark
$15.57 /

-0.11 (-0.70%)

KALV KalVista
$14.24 /

-0.285 (-1.96%)

EXEL Exelixis
$16.36 /

+0.68 (+4.34%)

BBBY Bed Bath & Beyond
$5.99 /

-0.12 (-1.96%)

AYI Acuity Brands
$159.51 /

+1.51 (+0.96%)

AXTI AXT Inc.
$7.00 /

+0.29 (+4.32%)

ADEA Adeia
$7.19 /

+0.54 (+8.12%)

TSLA Tesla
$242.24 /

-23.1 (-8.71%)

10/04/22 Morgan Stanley
Morgan Stanley expects Tesla shares to give back recent relative strength
10/03/22 JPMorgan
Tesla price target raised to $153 from $137 at JPMorgan
10/03/22 Oppenheimer
Tesla should be bought on any weakness following Q3 deliveries, says Oppenheimer
10/03/22 Wedbush
Wedbush remains bullish onTesla as Q3 deliveries come up short
POSH Poshmark
$15.57 /

-0.11 (-0.70%)

10/04/22 Needham
RealReal may be target for acquisition after Poshmark, says Needham
10/04/22 Wedbush
Poshmark downgraded to Neutral from Outperform at Wedbush
08/15/22 Barclays
Poshmark upgraded to Overweight from Equal Weight at Barclays
07/27/22 MKM Partners
MKM assumes Poshmark with Neutral rating, cites near-term profitability concerns
ADEA Adeia
$7.19 /

+0.54 (+8.12%)

EXEL Exelixis
$16.36 /

+0.68 (+4.34%)

08/10/22 Cowen
Exelixis price target raised to $26 from $24 at Cowen
07/26/22 Piper Sandler
Exelixis price target raised to $32 from $30 at Piper Sandler
06/23/22 BMO Capital
Exelixis initiated with an Outperform at BMO Capital
05/19/22 Piper Sandler
Exelixis sold off on Cabometyx patent trial comments, says Piper Sandler
BBBY Bed Bath & Beyond
$5.99 /

-0.12 (-1.96%)

09/30/22 Odeon Capital
Odeon upgrades Bed Bath & Beyond to Hold with things 'moving in right direction'
09/30/22 Odeon Capital
Bed Bath & Beyond upgraded to Hold from Sell at Odeon Capital
09/01/22 BofA
BofA cuts Bed Bath & Beyond target to $2 on continuing cash burn
09/01/22 Raymond James
Raymond James downgrades Bed Bath & Beyond to sell on 'abysmal' trends
RIVN Rivian Automotive
$31.89 /

-1.025 (-3.11%)

10/04/22 Truist
Rivian Automotive's affirmed FY22 production outweighs Q3 shortfall, says Truist
09/28/22 Truist
Truist starts 'diversified mobility powerhouse' Rivian Automotive at Buy
09/28/22 Truist
Rivian Automotive initiated with a Buy at Truist
09/28/22 RBC Capital
RBC cuts Rivian target, production forecasts but stays Outperform
AYI Acuity Brands
$159.51 /

+1.51 (+0.96%)

09/27/22 William Blair
Acuity survey shows waning impact from price hikes, says William Blair
07/01/22 Oppenheimer
Acuity Brands delivers 'strong organic beat' in Q3, says Oppenheimer
07/01/22 Baird
Acuity Brands price target raised to $190 from $188 at Baird
06/27/22 Credit Suisse
Acuity Brands price target lowered to $211 from $241 at Credit Suisse
KALV KalVista
$14.24 /

-0.285 (-1.96%)

06/08/22 Stifel
KalVista acute HAE market opportunity 'underappreciated,' says Stifel
11/10/21 Roth Capital
KalVista FDA meeting feedback 'quite positive,' says Roth Capital
RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

09/30/22 Chardan
Rocket Pharmaceuticals price target raised to $65 from $62 at Chardan
09/30/22 Evercore ISI
Rocket Pharmaceuticals price target raised to $75 from $65 at Evercore ISI
09/27/22 UBS
Rocket Pharmaceuticals price target cut to $62, named new top SMID pick at UBS
09/21/22 Baird
Renovacor downgraded to Neutral from Outperform at Baird
AXTI AXT Inc.
$7.00 /

+0.29 (+4.32%)

10/04/22 B. Riley
AXT Inc. price target lowered to $6.50 from $8 at B. Riley
10/03/22 BWS Financial
AXT Inc. may have won spot in iPhone 14 Pro and Pro Max, says BWS Financial
06/27/22 Needham
AXT Inc. initiated with a Buy at Needham
04/29/22 Northland
AXT Inc. price target lowered to $12 from $15 at Northland
TSLA Tesla
$242.24 /

-23.1 (-8.71%)

RIVN Rivian Automotive
$31.89 /

-1.025 (-3.11%)

RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

POSH Poshmark
$15.57 /

-0.11 (-0.70%)

KALV KalVista
$14.24 /

-0.285 (-1.96%)

EXEL Exelixis
$16.36 /

+0.68 (+4.34%)

BBBY Bed Bath & Beyond
$5.99 /

-0.12 (-1.96%)

AYI Acuity Brands
$159.51 /

+1.51 (+0.96%)

AXTI AXT Inc.
$7.00 /

+0.29 (+4.32%)

  • 04
    Oct
  • 10
    Nov
TSLA Tesla
$242.24 /

-23.1 (-8.71%)

RIVN Rivian Automotive
$31.89 /

-1.025 (-3.11%)

POSH Poshmark
$15.57 /

-0.11 (-0.70%)

BBBY Bed Bath & Beyond
$5.99 /

-0.12 (-1.96%)

TSLA Tesla
$242.24 /

-23.1 (-8.71%)

RIVN Rivian Automotive
$31.89 /

-1.025 (-3.11%)

RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

POSH Poshmark
$15.57 /

-0.11 (-0.70%)

KALV KalVista
$14.24 /

-0.285 (-1.96%)

BBBY Bed Bath & Beyond
$5.99 /

-0.12 (-1.96%)

AYI Acuity Brands
$159.51 /

+1.51 (+0.96%)

AXTI AXT Inc.
$7.00 /

+0.29 (+4.32%)

TSLA Tesla
$242.24 /

-23.1 (-8.71%)

RIVN Rivian Automotive
$31.89 /

-1.025 (-3.11%)

BBBY Bed Bath & Beyond
$5.99 /

-0.12 (-1.96%)

ADEA Adeia
$7.19 /

+0.54 (+8.12%)

Syndicate
Rocket Pharmaceuticals 6.8M share Spot Secondary priced at $14.75 » 06:21
10/04/22
10/04
06:21
10/04/22
06:21
RCKT

Rocket Pharmaceuticals

$15.49 /

-0.49 (-3.07%)

The deal priced below…

The deal priced below last closing price of $15.50. Morgan Stanley, JMP Securities and SVB Securities are acting as joint book running managers for the offering.

ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

09/30/22 Chardan
Rocket Pharmaceuticals price target raised to $65 from $62 at Chardan
09/30/22 Evercore ISI
Rocket Pharmaceuticals price target raised to $75 from $65 at Evercore ISI
09/27/22 UBS
Rocket Pharmaceuticals price target cut to $62, named new top SMID pick at UBS
09/21/22 Baird
Renovacor downgraded to Neutral from Outperform at Baird
RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

  • 04
    Oct
RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

On The Fly
Fly Intel: After-Hours Movers » 17:54
10/03/22
10/03
17:54
10/03/22
17:54
AERC

AeroClean

$3.19 /

+0.31 (+10.76%)

, BLKB

Blackbaud

$44.98 /

+0.92 (+2.09%)

, RIVN

Rivian Automotive

$31.89 /

-1.025 (-3.11%)

, AMRX

Amneal Pharmaceuticals

$2.08 /

+0.04 (+1.97%)

, AXTI

AXT Inc.

$7.00 /

+0.29 (+4.32%)

, TYRA

Tyra Biosciences

$7.76 /

-1.36 (-14.91%)

, RCKT

Rocket Pharmaceuticals

$15.49 /

-0.49 (-3.07%)

Check out this evening's…

ShowHide Related Items >><<
TYRA Tyra Biosciences
$7.76 /

-1.36 (-14.91%)

RIVN Rivian Automotive
$31.89 /

-1.025 (-3.11%)

RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

BLKB Blackbaud
$44.98 /

+0.92 (+2.09%)

AXTI AXT Inc.
$7.00 /

+0.29 (+4.32%)

AMRX Amneal Pharmaceuticals
$2.08 /

+0.04 (+1.97%)

AERC AeroClean
$3.19 /

+0.31 (+10.76%)

AERC AeroClean
$3.19 /

+0.31 (+10.76%)

08/17/22 Benchmark
AeroClean upgraded to Speculative Buy at Benchmark after 'steep drop'
08/17/22 Benchmark
AeroClean upgraded to Speculative Buy from Hold at Benchmark
06/14/22 Benchmark
AeroClean downgraded to Hold at Benchmark after rapid rally
06/14/22 Benchmark
AeroClean downgraded to Hold from Buy at Benchmark
BLKB Blackbaud
$44.98 /

+0.92 (+2.09%)

02/24/22 Baird
Blackbaud price target lowered to $70 from $85 at Baird
RIVN Rivian Automotive
$31.89 /

-1.025 (-3.11%)

09/28/22 Truist
Truist starts 'diversified mobility powerhouse' Rivian Automotive at Buy
09/28/22 Truist
Rivian Automotive initiated with a Buy at Truist
09/28/22 RBC Capital
RBC cuts Rivian target, production forecasts but stays Outperform
09/14/22 Needham
Rivian Automotive initiated with a Hold at Needham
AMRX Amneal Pharmaceuticals
$2.08 /

+0.04 (+1.97%)

08/18/22 JPMorgan
Generic manufacturer selloff yesterday 'very much overdone,' says JPMorgan
04/28/22 Barclays
Amneal Pharmaceuticals price target lowered to $7 from $8 at Barclays
AXTI AXT Inc.
$7.00 /

+0.29 (+4.32%)

10/03/22 BWS Financial
AXT Inc. may have won spot in iPhone 14 Pro and Pro Max, says BWS Financial
06/27/22 Needham
AXT Inc. initiated with a Buy at Needham
04/29/22 Northland
AXT Inc. price target lowered to $12 from $15 at Northland
04/29/22 B. Riley
AXT Inc. price target lowered to $8 from $9.50 at B. Riley
TYRA Tyra Biosciences
$7.76 /

-1.36 (-14.91%)

06/23/22 H.C. Wainwright
Tyra Biosciences initiated with a Buy at H.C. Wainwright
03/08/22 Jefferies
Jefferies upgrades Tyra Biosciences to Buy on valuation after 58% pullback
03/08/22 Jefferies
Tyra Biosciences upgraded to Buy from Hold at Jefferies
11/08/21 Jefferies
Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts
RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

09/30/22 Chardan
Rocket Pharmaceuticals price target raised to $65 from $62 at Chardan
09/30/22 Evercore ISI
Rocket Pharmaceuticals price target raised to $75 from $65 at Evercore ISI
09/27/22 UBS
Rocket Pharmaceuticals price target cut to $62, named new top SMID pick at UBS
09/21/22 Baird
Renovacor downgraded to Neutral from Outperform at Baird
RIVN Rivian Automotive
$31.89 /

-1.025 (-3.11%)

RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

BLKB Blackbaud
$44.98 /

+0.92 (+2.09%)

AXTI AXT Inc.
$7.00 /

+0.29 (+4.32%)

AMRX Amneal Pharmaceuticals
$2.08 /

+0.04 (+1.97%)

AERC AeroClean
$3.19 /

+0.31 (+10.76%)

  • 04
    Oct
  • 24
    Nov
  • 10
    Nov
RIVN Rivian Automotive
$31.89 /

-1.025 (-3.11%)

RIVN Rivian Automotive
$31.89 /

-1.025 (-3.11%)

RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

AXTI AXT Inc.
$7.00 /

+0.29 (+4.32%)

AERC AeroClean
$3.19 /

+0.31 (+10.76%)

TYRA Tyra Biosciences
$7.76 /

-1.36 (-14.91%)

RIVN Rivian Automotive
$31.89 /

-1.025 (-3.11%)

Hot Stocks
Rocket Pharmaceuticals drops 6% to $14.49 after $100M common stock offering  16:56
10/03/22
10/03
16:56
10/03/22
16:56
RCKT

Rocket Pharmaceuticals

$15.49 /

-0.49 (-3.07%)

 
ShowHide Related Items >><<
RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

09/30/22 Chardan
Rocket Pharmaceuticals price target raised to $65 from $62 at Chardan
09/30/22 Evercore ISI
Rocket Pharmaceuticals price target raised to $75 from $65 at Evercore ISI
09/27/22 UBS
Rocket Pharmaceuticals price target cut to $62, named new top SMID pick at UBS
09/21/22 Baird
Renovacor downgraded to Neutral from Outperform at Baird
RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

RCKT Rocket Pharmaceuticals
$15.49 /

-0.49 (-3.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.